Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas

详细信息    查看全文

• 作者：CongXin Dai (1)
  Feng Cai (1)
  Kuo Chu Hwang (2)
  YongMao Zhou (3)
  ZiZhu Zhang (4)
  XiaoHai Liu (1)
  SiHai Ma (1)
  YaKun Yang (1)
  Yong Yao (1)
  Ming Feng (1)
  XinJie Bao (1)
  GuiLin Li (1)
  JunJi Wei (1)
  YongHui Jiao (1)
  ZhenQing Wei (1)
  WenBin Ma (1)
  RenZhi Wang (1)
  
• 关键词：nonfunctional pituitary adenomas ; folate receptor ; nanoparticles ; boron neutron capture therapy
• 刊名：Science China Life Sciences
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：56
• 期：2
• 页码：163-173
• 全文大小：1025KB
• 参考文献：1. Asa S L, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer, 2002, 2: 836鈥?49 CrossRef
  2. Asa S L, Kovacs K. Clinically non-functioning human pituitary adenomas. Can J Neurol Sci, 1992, 19: 228鈥?35
  3. Chang E F, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg, 2008, 108: 736鈥?45 CrossRef
  4. Losa M, Picozzi P, Motta M, et al. The role of radiation therapy in the management of non-functioning pituitary adenomas. J Endocrinol Invest, 2011, 34: 623鈥?29
  5. Pollock B E, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys, 2008, 70: 1325鈥?329 CrossRef
  6. Feigl G C, Pistracher K, Berghold A, et al. Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. J Neurosurg, 2010, 113(Suppl): 153鈥?59
  7. Barth R F. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot, 2009, 67: S3鈥揝6 CrossRef
  8. Pisarev M A, Dagrosa M A, Juvenal G J. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol, 2007, 51: 852鈥?56 CrossRef
  9. Barth R F, Coderre J A, Vicente M G, et al. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res, 2005, 11: 3987鈥?002 CrossRef
  10. Barth R F, Soloway A H, Fairchild R G, et al. Boron neutron capture therapy for cancer. Realities and prospects. Cancer, 1992, 70: 2995鈥?007
  11. Barth R F, Yang W, Rotaru J H, et al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys, 2000, 47: 209鈥?18 CrossRef
  12. Panov V, Salomon Y, Kabalka G W, et al. Uptake and washout of borocaptate sodium and borono-phenylalanine in cultured melanoma cells: a multi-nuclear NMR study. Radiat Res, 2000, 154: 104鈥?12 CrossRef
  13. Sudimack J, Lee R J. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev, 2000, 41: 147鈥?62 CrossRef
  14. Hwang K C, Lai P D, Chiang C S, et al. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells. Biomaterials, 2010, 31: 8419鈥?425 CrossRef
  15. Evans C O, Reddy P, Brat D J, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res, 2003, 63: 4218鈥?224
  16. Liu X, Ma S, Yao Y, et al. Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior. Neurosurgery, 2012, 70: 1274鈥?280 CrossRef
  17. Ke G, Sun Z, Shen F, et al. The study of physics and thermal characteristics for in-hospital neutron irradiator (IHNI). Appl Radiat Isot, 2009, 67: S234鈥揝237 CrossRef
  18. Linko S, Revitzer H, Zilliacus R, et al. Boron detection from blood samples by ICP-AES and ICP-MS during boron neutron capture therapy. Scand J Clin Lab Invest, 2008, 68: 696鈥?02 CrossRef
  19. Zhang L, Xing D, Chen M. Bim(L) displacing Bcl-x(L) promotes Bax translocation during TNFalpha-induced apoptosis. Apoptosis, 2008, 13: 950鈥?58 CrossRef
  20. Kawabata S, Miyatake S, Nonoguchi N, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot, 2009, 67: S15鈥揝18 CrossRef
  21. Santa C G, Gonzalez S J, Bertotti J, et al. First application of dynamic infrared imaging in boron neutron capture therapy for cutaneous malignant melanoma. Med Phys, 2009, 36: 4519鈥?529 CrossRef
  22. Aihara T, Hiratsuka J, Morita N, et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck, 2006, 28: 850鈥?55 CrossRef
  23. Kato I, Fujita Y, Maruhashi A, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot, 2009, 67: S37鈥揝42 CrossRef
  24. Suzuki M, Sakurai Y, Masunaga S, et al. Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors. Int J Radiat Oncol Biol Phys, 2004, 58: 892鈥?96 CrossRef
  25. Kimura Y, Ariyoshi Y, Shimahara M, et al. Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl Radiat Isot, 2009, 67: S47鈥揝49 CrossRef
  26. Colao A, Grasso L F, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother, 2011, 12: 1561鈥?570 CrossRef
  27. Evans C O, Young A N, Brown M R, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab, 2001, 86: 3097鈥?107 CrossRef
  28. Thirumamagal B T, Zhao X B, Bandyopadhyaya A K, et al. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem, 2006, 17: 1141鈥?150 CrossRef
  29. Stephenson S M, Yang W, Stevens P J, et al. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res, 2003, 23: 3341鈥?345
  30. Shukla S, Wu G, Chatterjee M, et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem, 2003, 14: 158鈥?67 CrossRef
  31. Sudimack J J, Adams D, Rotaru J, et al. Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells / in vitro for neutron capture therapy. Pharm Res, 2002, 19: 1502鈥?508 CrossRef
  32. Wang P, Zhen H, Jiang X, et al. Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax. BMC Cancer, 2010, 10: 661 CrossRef
  33. Yanagihara K, Nii M, Numoto M, et al. Radiation-induced apoptotic cell death in human gastric epithelial tumour cells; correlation between mitotic death and apoptosis. Int J Radiat Biol, 1995, 67: 677鈥?85 CrossRef
  34. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 1997, 275: 1129鈥?132 CrossRef
  35. Mahajan N P, Linder K, Berry G, et al. Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer. Nat Biotechnol, 1998, 16: 547鈥?52 CrossRef
  36. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 2003, 423: 456鈥?61 CrossRef
  37. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature, 1998, 391: 496鈥?99 CrossRef
  
• 作者单位：CongXin Dai (1)
  Feng Cai (1)
  Kuo Chu Hwang (2)
  YongMao Zhou (3)
  ZiZhu Zhang (4)
  XiaoHai Liu (1)
  SiHai Ma (1)
  YaKun Yang (1)
  Yong Yao (1)
  Ming Feng (1)
  XinJie Bao (1)
  GuiLin Li (1)
  JunJi Wei (1)
  YongHui Jiao (1)
  ZhenQing Wei (1)
  WenBin Ma (1)
  RenZhi Wang (1)
  
  1. Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
  2. Department of Chemistry, Tsing Hua University, Hsinchu, 300 43, Taiwan, China
  3. China Zhongyuan Engineering Corporation, China National Nuclear Corporation, Beijing, 100191, China
  4. China Nuclear Industry Beijing 410 Hospital of China Institute of Atomic Energy, Beijing, 101213, China
  

文摘

Invasive nonfunctional pituitary adenomas (NFPAs) are difficult to completely resect and often develop tumor recurrence after initial surgery. Currently, no medications are clinically effective in the control of NFPA. Although radiation therapy and radiosurgery are useful to prevent tumor regrowth, they are frequently withheld because of severe complications. Boron neutron capture therapy (BNCT) is a binary radiotherapy that selectively and maximally damages tumor cells without harming the surrounding normal tissue. Folate receptor (FR)-targeted boron-10 containing carbon nanoparticles is a novel boron delivery agent that can be selectively taken up by FR-expressing cells via FR-mediated endocytosis. In this study, FR-targeted boron-10 containing carbon nanoparticles were selectively taken up by NFPAs cells expressing FR but not other types of non-FR expressing pituitary adenomas. After incubation with boron-10 containing carbon nanoparticles and following irradiation with thermal neutrons, the cell viability of NFPAs was significantly decreased, while apoptotic cells were simultaneously increased. However, cells administered the same dose of FR-targeted boron-10 containing carbon nanoparticles without neutron irradiation or received the same neutron irradiation alone did not show significant decrease in cell viability or increase in apoptotic cells. The expression of Bcl-2 was down-regulated and the expression of Bax was up-regulated in NFPAs after treatment with FR-mediated BNCT. In conclusion, FR-targeted boron-10 containing carbon nanoparticles may be an ideal delivery system of boron to NFPAs cells for BNCT. Furthermore, our study also provides a novel insight into therapeutic strategies for invasive NFPA refractory to conventional therapy, while exploring these new applications of BNCT for tumors, especially benign tumors.